Announcements Trials
Browse Landscape

Phase

Phase 3 12Phase 2 7Phase 2/3 4Phase 1 3Phase NA 2Phase 4 2

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 1

Conditions

Fatigue 2Neoplasms 1Multiple Endocrine Neoplasia Type 1 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Methylphenidate × Clear all
NCT02361125 2022-01-04

Patient Controlled Administration of Methylphenidate for Cancer Related Fatigue - PRN Methylphenidate

M.D. Anderson Cancer Center

Phase 1 Completed
31 enrolled

Fatigue

NCT01164956 2019-04-26

Methylphenidate for Cancer-Related Fatigue

Dana-Farber Cancer Institute

Phase 1 Terminated
3 enrolled 7 charts

Fatigue, Neoplasms

NCT01202734 2014-05-16

A Pharmacokinetics and Safety of Methylphenidate HCl in Healthy Japanese Adult Male Volunteers

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 1 Completed
10 enrolled
Endocrine

Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡